Extra-corporeal membrane oxygenation (ECMO) for pulmonary and cardiac failure

External life support
Number of report

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for Extra-corporeal membrane oxygenation (ECMO) for pulmonary and cardiac failure.

Both veno-venous and veno-arterial ECMO is considered.

The use of ECMO is considered in the following situations:

  • Acute respiratory distress syndrome (VV-ECMO)
  • Deterioration of chronic advanced heart failure (VA-ECMO)
  • Post-cardiotomy cardiogenic shock (VA-ECMO)
  • Post-myocardial infarction cardiogenic shock (VA-ECMO)

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

Manufacturers of extra-corporeal membrane oxygenation devices for pulmonary and cardiac failure report include:

  • Abbott Vascular (CentriMag, PediVAS)
  • Fresenius / XENIOS AG (Medos device)
  • Getinge (CARDIOHELP System, Rotaflow Centrifugal Pump System, PLS System)
  • Hemovent GmbH (Portable ECMO system)
  • Medtronic (BPX-80, BP-50)
  • Terumo (CAPIOX SP Centrifugal Pump)

Table of content is not available at the moment.

There are no relevant news at the moment
(we accept only company emails)